【作者】 李铁； 娄广媛； 吕汪霞； 张沂平；

【Author】 Li Tie Lou Guang-yuan Lv Wang-xia Zhang Yi-ping Department of Chemotherapy,Zhejiang Cancer Hospital,hangzhou 310022

【机构】 浙江省肿瘤医院化疗中心；

【摘要】 目的观察 Alimta 单药治疗晚期复治的非小细胞肺癌的近期疗效及毒副反应。方法 17位晚期复治的非小细胞肺癌患者接受 Alimta 500mg/m~2化疗,21天为一个周期。结果总有效率(CR+PR)为11.8%,临床获益率(CR+PR+SD)为76.5%。主要毒副反应为骨髓抑制。结论 Alimta 治疗晚期复治的非小细胞肺癌取得较明显的临床获益率,且毒副反应可耐受。更多还原

【Abstract】 Objective To evaluate the clinical efficiency and toxicity of Alimta in treatment of advanced retreated non-small cell Lung cancer. Methods 17 advanced retreated patients received Alimta at a dose of 500mg/m~2, the chemotherapy was repeated every 21 days on two cycles.Results Among 17 patients,the total response was 11.8%,the clinical benefit rate was 76.5%,and the main toxicity was hematological toxicties.Conclusion Alimta is effective in treatment of advanced retreated non-small lung cancer and the toxicity can be well acceptale.更多还原